Neurodegenerative diseases: Anti-epileptic drug shows benefit in AD mouse model

Nature Reviews Drug Discovery

Volumn 11, Issue 10, 2012, Pages 748-749

  Tse, Man Tsuey ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTICONVULSIVE AGENT; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; NEUROPEPTIDE Y; PHENYTOIN; PREGABALIN; PROTEIN FOS; VALPROIC ACID; VIGABATRIN;

ALZHEIMER DISEASE; ANTICONVULSANT ACTIVITY; BRAIN DYSFUNCTION; BRAIN LEVEL; COGNITIVE DEFECT; DISEASE PREDISPOSITION; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; EPILEPSY; FOOD AND DRUG ADMINISTRATION; HIPPOCAMPUS; HUMAN; HYPERACTIVITY; MEMORY DISORDER; NERVE CELL NETWORK; NONHUMAN; NOTE; OSMOTIC PUMP; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SEIZURE; TREATMENT DURATION;

EID: 84867030084     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3850     Document Type: Note

References (1)

1. Sanchez, P. E. et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc. Natl Acad. Sci. USA 6 Aug 2012 (doi: 10.1073/pnas. 1121081109)